Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Current Leases (2023 - 2025)

IGC Pharma has reported Current Leases over the past 3 years, most recently at $9000.0 for Q3 2025.

  • Quarterly Current Leases fell 93.28% to $9000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $9000.0 through Sep 2025, down 93.28% year-over-year, with the annual reading at $94000.0 for FY2025, 24.19% down from the prior year.
  • Current Leases was $9000.0 for Q3 2025 at IGC Pharma, down from $62000.0 in the prior quarter.
  • Over five years, Current Leases peaked at $134000.0 in Q3 2024 and troughed at $9000.0 in Q3 2025.
  • The 3-year median for Current Leases is $124000.0 (2023), against an average of $104111.1.
  • Year-over-year, Current Leases changed 0.0% in 2024 and then plummeted 93.28% in 2025.
  • A 3-year view of Current Leases shows it stood at $124000.0 in 2023, then changed by 0.0% to $124000.0 in 2024, then crashed by 92.74% to $9000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Current Leases are $9000.0 (Q3 2025), $62000.0 (Q2 2025), and $94000.0 (Q1 2025).